Latest Earnings Results: Q3 '26
Estimated EPS
-$0.05
Reported EPS
-$0.13
Surprise
-160%
Estimated Rev
$168.68M
Reported Rev
$169.77M
Surprise
+0.65%
Starling Oncology's FY2026 updated guidance is revenue of $650M, gross profit of $107M, Adjusted EBITDA of $4M, and Free Cash Flow of $5M.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.04 | -- | -- | N/A |
Q3 '26 | -$0.05 | -$0.13 | -160.00% | MISSED |
Q2 '26 | -$0.06 | -$0.08 | -25.00% | MISSED |
Q1 '26 | -- | -$0.02 | -- | N/A |